Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program
Michael J. Satlin, Patricia J. Simner, Christine M Slover, Yoshinori Yamano, Tsutae Den Nagata, Simon Portsmouth
Abstract
Cefiderocol is an option for infections caused by multidrug-resistant Pseudomonas aeruginosa , but its in vitro activity against these isolates and its clinical effectiveness for isolates with MICs of >1 μg/mL is unclear. We investigated the in vitro activity of cefiderocol against P. aeruginosa isolates collected from patients treated with cefiderocol through the compassionate use program and assessed physician-reported clinical response and 28-day all-cause mortality by cefiderocol MIC values. P. aeruginosa isolates underwent susceptibility testing to cefiderocol and comparator agents by using reference broth microdilution.
Topics & Concepts
Pseudomonas aeruginosaBroth microdilutionBiologyMicrobiologyMedicineMinimum inhibitory concentrationAntibioticsBacteriaGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyAntibiotic Use and Resistance